Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danny Soares

Facial Plastic Surgery Atlanta, GA Medical Doctor

NPI 1952568370 CMS profile 646803

4553 N Shallowford Rd, Suite 20B, Atlanta, GA 30338

Open in the dashboard

General payments

$16,981

57 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danny Soares of Atlanta, GA is reported in the CMS Open Payments database as having received $16,981 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,379 13
2024 General $2,571 16
2023 General $1,488 10
2022 General $119 3
2021 General $39 1
2020 General $219 3
2019 General $1,166 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danny Soares
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Danny Soares were reported at $11,379. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Danny Soares Facial Plastic Surgery median Middle half National median
2019 $1,166 $225 $92–$651 $163
2020 $219 $132 $45–$323 $114
2021 $39 $186 $67–$558 $132
2022 $119 $218 $83–$594 $149
2023 $1,488 $237 $94–$564 $160
2024 $2,571 $233 $104–$575 $164
2025 $11,379 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Revance Therapeutics, Inc. $11,618 10 payments
  2. Merz North America, Inc. $4,802 30 payments
  3. Galderma Laboratories, L.P. $267 10 payments
  4. Apyx Medical Corporation $136 2 payments
  5. Sientra, Inc. $59 1 payment
  6. Allergan Inc. $45 2 payments
  7. Innovation Technologies Inc $34 1 payment
  8. E.R. Squibb & Sons, L.L.C. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,600 4 payments
  2. Food and Beverage $3,906 46 payments
  3. Travel and Lodging $3,422 6 payments
  4. Education $54 1 payment
Products named General payments · program years 2019–2025
  1. DAXXIFY $11,618 10 payments
  2. Xeomin Dermatology $1,933 11 payments
  3. ASCLERA $804 5 payments
  4. Xeomin musculoskeletal $665 6 payments
  5. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $59 1 payment
  6. Irrisept $34 1 payment
  7. DYSPORT $24 1 payment
  8. ELIQUIS $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

468

Median for Otolaryngology: 297

Drug cost

$2,898

Median for Otolaryngology: $6,314

Branded share of claims

43.2%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 75 $860
Methylprednisolone Generic 91 $679
Cephalexin Generic 104 $490
Ondansetron Odt Ondansetron Brand 45 $395
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 82 $343
Clindamycin Hcl Generic 18 $53
Zolpidem Tartrate Generic 19 $41
Alprazolam Generic 12 $22
Lorazepam Generic 22 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $724
$724 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $422
$422 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record